Baby Boom Goes Bust, Signaling Hard Times: U.S. Coronavirus Blog - Across America, US - States expand vaccine eligibility; officials warn against easing restrictions; pharmaceutical giants partner on vaccine.
MORE
LANSING, MI. â Parts of the marijuana plant could be a key to treating one of COVID-19âs deadly symptoms.Â
The immune system responds when exposed to COVID-19, but sometimes so aggressively it affects lung function and makes it harder to breathe. Thatâs where a new drug containing cannabinoids, a family of compounds contained in the marijuana plant, comes in.Â
Norbert Kaminski, a Michigan State University professor of pharmacology and toxicology, is working with GB Sciences, a biopharmaceutical company, to develop a drug that prevents the lung inflammation that some experience after contracting COVID-19 that can lead to trouble breathing and death.Â
How the cannabis plant could fight symptoms of COVID-19 fox17online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fox17online.com Daily Mail and Mail on Sunday newspapers.
LANSING Parts of the marijuana plant could be a key to treating one of COVID-19’s deadly symptoms.
The immune system responds when exposed to COVID-19, but sometimes so aggressively it affects lung function and makes it harder to breathe.
That’s where a new drug containing cannabinoids, a family of compounds contained in the marijuana plant, comes in.
Norbert Kaminski, a Michigan State University professor of pharmacology and toxicology, is working with GB Sciences, a biopharmaceutical company, to develop a drug that prevents the lung inflammation that some experience after contracting COVID-19 that can lead to trouble breathing and death.
(1)
LAS VEGAS, NV / ACCESSWIRE / January 25, 2021 / GB Sciences, Inc. (OTCQB:GBLX), through GBS Global Biopharma, Inc. ( GBS ), has executed a Sponsored Research Agreement with Michigan State University (MSU) to obtain valuable proof-of-concept data to support the use of their new proprietary cannabinoid containing complex mixtures (CCCM) for the treatment of Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) in COVID-19 patients. CRS, MAS, and ARDS are the leading causes of deaths in COVID-19 patients. GBS CCCM were designed to reduce the life-threatening levels of specific cytokines and pro-inflammatory processes triggered by SARS-CoV-2 infections, while preserving those immune functions and cytokines that are necessary for fighting the viral infection.